Drug resistance

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
Tuesday, March 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GPCR, Gene, Immunotherapy, Patient, Immunosuppression, PAR2, ICB, Research, Tumor microenvironment, Cancer, G protein-coupled receptor, IND, AACR, Gq alpha subunit, Therapy, Drug resistance, Module (mathematics)

PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.

Key Points: 
  • PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.
  • Its upregulation across a variety of cancer types and expression on diverse cells within the tumor microenvironment underscore PAR2’s critical role in cancer development.
  • Remarkably, when compared to its most advanced competitors positioned in other therapeutic areas, this candidate has demonstrated clear differentiated features.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, commented: “We are excited to present our newest findings on DT-9045 at AACR.

TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Boston Scientific, Werewolf, Growth, Genentech, Strategic management, CFO, Business, Novartis, Trustee, Patient, Chairperson, Tuck School of Business, CBO, Sale, Business development, Acquisition, University, IPO, Belharra, Columbia Law School, Doctor of Philosophy, Senior, MBA, Clinical trial, Therapy, Guidant, DePauw University, Claremont McKenna College, Drug resistance, Celgene, FDA, Economics, Corporation, Management

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
  • "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry.
  • Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership.

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Retrieved on: 
Friday, March 15, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, SLL, BMY, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Bone marrow, Caregiver, Patient, Lymphocytosis, City, CRS, Commercial, Bristol Myers Squibb, BTK, MRD, Cytokine release syndrome, Division, Drug resistance, Multimedia, Blood, Associate professor, Food, Pharmaceutical industry

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
  • “For years, attempts to bring other CAR T cell therapies to patients with relapsed or refractory CLL or SLL met challenges and found little success.
  • After relapsing or becoming refractory to these therapies, patients have few options and poor outcomes, including lack of durable complete responses.

IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cantor Fitzgerald, Ohio State University, Development, J. P. Morgan, Information technology, Novo Nordisk, NSCLC, Genentech, University, Brad, Patient, Research, Sale, Acquisition, Lung cancer, Research and development, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, RBC Capital Markets, Forma, Drug resistance, Pharmaceutical industry

Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.

Key Points: 
  • Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.
  • He played a key role in the company's evolution from early research to a global commercial oncology company, and its subsequent acquisition by Takeda.
  • He led Selecta through several significant financing and strategic transactions, including a $730 million licensing agreement for its lead program.
  • “I look forward to working with Tim, Ben, and the team at IDRx to grow the Company with the backbone of IDRX-42,” said Mr. Dahms.

Anivive to Present Groundbreaking Research on First Systemic Antifungal Vaccine at World Vaccine Congress

Retrieved on: 
Thursday, April 4, 2024
Fungal infection, Health, Congress, Infection, Risk, Public, Coccidioidomycosis, Research, University, Vaccine, Immune system, Immunodeficiency, Environmental health, Drug resistance

WASHINGTON, April 4, 2024 /PRNewswire/ -- Anivive Lifesciences, is set to unveil groundbreaking research at the upcoming World Vaccine Congress , where they will present findings on the development of the world's first systemic antifungal vaccine – A solution for both ends of the leash.

Key Points: 
  • WASHINGTON, April 4, 2024 /PRNewswire/ -- Anivive Lifesciences, is set to unveil groundbreaking research at the upcoming World Vaccine Congress , where they will present findings on the development of the world's first systemic antifungal vaccine – A solution for both ends of the leash.
  • I am honored to share our findings at the World Vaccine Congress and contribute to the global dialogue on vaccine innovation."
  • The World Vaccine Congress serves as a premier platform for sharing cutting-edge research and fostering collaboration among experts in the field of vaccinology.
  • For more information about Dr. Robb's presentation and the World Vaccine Congress, please visit Anivive.com

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Neoplasm, Cetuximab, Jefferies Group, Research, Chemistry, Nivolumab, Table, NETS, IRS, NK, Pancreatic cancer, Head, 5T4, DCR, Investigational New Drug, Escape Room, SCCHN, Interim, MD Anderson Cancer Center, Congress, Net, Three Months, International Financial Reporting Standards, CMC, Immune system, International, ESMO, Neutrophil extracellular traps, University, STAT3, AACR, CM24, Conference, Tumor microenvironment, MOA, IND, Insurance, Acquisition, ADS, Drug resistance, Food, Average cost, CEACAM1, PDAC, Administration, Patient, Pharmaceutical industry

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Retrieved on: 
Tuesday, March 5, 2024
Drug resistance, Neoplasm, Drug design, AACR, Therapy, Patient, ACRV, Medicine, AP3, PKMYT1, WEE1, Gemcitabine, Pharmaceutical industry

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company will be presenting data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5 – 10, 2024 in San Diego, CA.

Key Points: 
  • “The data we will be presenting reinforce the broad applicability of our highly differentiated, actionable AP3 platform technology,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “ACR-2316 is our first fully internally-discovered development candidate which was rapidly generated through co-crystallography-based drug design and uniquely leverages AP3.
  • Our platform enables us to generate selective, potent single-agent active molecules, such as ACR-2316, that we believe can address some of the key limitations of current WEE1 and PKMYT1 inhibitors.
  • We look forward to presenting these two datasets at AACR next month.”

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Retrieved on: 
Tuesday, February 27, 2024
Head, Neoplasm, DCR, Cetuximab, ESMO, Aes, Drug resistance, Escape Room, Immunotherapy, SCCHN, University, Nausea, Squamous-cell carcinoma, Tumor microenvironment, Patient, Congress, HPV, Plasma, Colorectal cancer, Pharmaceutical industry

REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (R/M SCCHN).

Key Points: 
  • The Phase 1/2 dose escalation study (NCT04474470) evaluated NT219 as a monotherapy in various indications and in combination with cetuximab in the treatment of R/M SCCHN and colorectal cancer.
  • As of cut-off date of January 25, 2024:
    Seventeen patients with R/M SCCHN were enrolled in the combination arm of NT219 + cetuximab.
  • The median number of prior lines of therapy was 2 and 94% of the patients received prior immunotherapy.
  • “We were encouraged to see anti-tumor activity in HPV negative patients,” said Dr. Michael Schickler, Purple Biotech’s Head of Clinical and Regulatory Affairs.

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Retrieved on: 
Thursday, February 22, 2024
Epilepsy, Pharmacology, DSM-IV codes, Research, GABAA, Drug resistance, 300X, Dizziness, Drug development, PAM, Volunteering, GAERS, Risk, Generalized tonic–clonic seizure, Deficit spending, Rat, Therapy, Ataxia, Memory, MED, Human, Cognition, Patient, Somnolence, Addiction, Partnership, Pharmaceutical industry

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.
  • The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model.
  • The study demonstrated full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg.
  • “The preclinical data published in Drug Development Research demonstrate BAER-101’s ability to fully suppress seizures in the GAERS model, a translational animal model for anti-seizure drug development with a documented high predictability of response in humans.